Source link : https://www.newshealth.biz/health-news/finerenone-reduces-t2d-onset-in-hf-with-preserved-ef/
MADRID, Spain — The nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone reduced the incidence of new-onset type 2 diabetes by approximately 25% in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), according to a prespecified subgroup analysis of the FINEARTS-HF trial. This is “very exciting, and quite a bonus treatment benefit on […]
Author : News Health
Publish date : 2024-09-10 16:47:05
Copyright for syndicated content belongs to the linked Source.